Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

医学 曲妥珠单抗 肿瘤科 结直肠癌 内科学 临床终点 队列 中期分析 化疗 瑞戈非尼 癌症 临床试验 乳腺癌
作者
John H. Strickler,Andrea Cercek,Salvatore Siena,Thierry André,Kimmie Ng,Eric Van Cutsem,Christina Wu,Andrew Scott Paulson,Joleen M. Hubbard,Andrew L. Coveler,Christos Fountzilas,Adel Kardosh,Pashtoon Murtaza Kasi,Heinz‐Josef Lenz,Kristen K. Ciombor,Elena Élez,David L. Bajor,Chiara Cremolini,Federico Sanchez,Michael Stecher
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:24 (5): 496-508 被引量:142
标识
DOI:10.1016/s1470-2045(23)00150-x
摘要

Summary

Background

HER2 is an actionable target in metastatic colorectal cancer. We assessed the activity of tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer.

Methods

MOUNTAINEER is a global, open-label, phase 2 study that enrolled patients aged 18 years and older with chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer at 34 sites (clinics and hospitals) in five countries (Belgium, France, Italy, Spain, and the USA). Initially, the study was designed as a single-cohort study, which was expanded following an interim analysis to include more patients. Initially, patients were given tucatinib (300 mg orally twice daily) plus intravenous trastuzumab (8 mg/kg as an initial loading dose, then 6 mg/kg every 21 days; cohort A) for the duration of treatment (until progression), and after expansion, patients were randomly assigned (4:3), using an interactive web response system and stratified by primary tumour location, to either tucatinib plus trastuzumab (cohort B) or tucatinib monotherapy (cohort C). The primary endpoint was confirmed objective response rate per blinded independent central review (BICR) for cohorts A and B combined and was assessed in patients in the full analysis set (ie, patients with HER2-positive disease who received at least one dose of study treatment). Safety was assessed in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, NCT03043313, and is ongoing.

Findings

Between Aug 8, 2017, and Sept 22, 2021, 117 patients were enrolled (45 in cohort A, 41 in cohort B, and 31 in cohort C), of whom 114 patients had locally assessed HER2-positive disease and received treatment (45 in cohort A, 39 in cohort B, and 30 in cohort C; full analysis set), and 116 patients received at least one dose of study treatment (45 in cohort A, 41 in cohort B, and 30 in cohort C; safety population). In the full analysis set, median age was 56·0 years (IQR 47–64), 66 (58%) were male, 48 (42%) were female, 88 (77%) were White, and six (5%) were Black or African American. As of data cutoff (March 28, 2022), in 84 patients from cohorts A and B in the full analysis set, the confirmed objective response rate per BICR was 38·1% (95% CI 27·7–49·3; three patients had a complete response and 29 had a partial response). In cohorts A and B, the most common adverse event was diarrhoea (55 [64%] of 86), the most common grade 3 or worse adverse event was hypertension (six [7%] of 86), and three (3%) patients had tucatinib-related serious adverse events (acute kidney injury, colitis, and fatigue). In cohort C, the most common adverse event was diarrhoea (ten [33%] of 30), the most common grade 3 or worse adverse events were increased alanine aminotransferase and aspartate aminotransferase (both two [7%]), and one (3%) patient had a tucatinib-related serious adverse event (overdose). No deaths were attributed to adverse events. All deaths in treated patients were due to disease progression.

Interpretation

Tucatinib plus trastuzumab had clinically meaningful anti-tumour activity and favourable tolerability. This treatment is the first US Food and Drug Administration-approved anti-HER2 regimen for metastatic colorectal cancer and is an important new treatment option for chemotherapy-refractory HER2-positive metastatic colorectal cancer.

Funding

Seagen and Merck & Co.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Verseau完成签到,获得积分10
1秒前
1秒前
小玲玲完成签到,获得积分10
2秒前
2秒前
zjx0925发布了新的文献求助20
2秒前
醍醐不醒完成签到,获得积分10
2秒前
zz发布了新的文献求助20
2秒前
流萤完成签到,获得积分10
2秒前
Ao发布了新的文献求助10
3秒前
风ff完成签到,获得积分10
3秒前
Verseau发布了新的文献求助10
4秒前
小白发布了新的文献求助10
4秒前
汉堡包应助龙傲天采纳,获得10
5秒前
尚尚完成签到 ,获得积分10
5秒前
kysl发布了新的文献求助10
5秒前
轩辕寄风完成签到,获得积分10
6秒前
高高发布了新的文献求助10
6秒前
爱吃肉肉的蚂蚁完成签到,获得积分10
7秒前
Robert_g完成签到,获得积分10
7秒前
完美世界应助Iris采纳,获得10
7秒前
聂立双发布了新的文献求助10
8秒前
8秒前
充电宝应助醍醐不醒采纳,获得10
9秒前
猪猪hero发布了新的文献求助10
9秒前
星辰大海应助梦梦采纳,获得10
9秒前
乐呵呵完成签到,获得积分10
9秒前
小玲玲发布了新的文献求助10
11秒前
liu完成签到,获得积分10
12秒前
悄悄发布了新的文献求助20
12秒前
我想@科研发布了新的文献求助10
12秒前
12秒前
何hao发布了新的文献求助80
13秒前
13秒前
FashionBoy应助梓榆采纳,获得10
13秒前
Chrischelsea发布了新的文献求助10
14秒前
多情的忆之完成签到,获得积分10
14秒前
14秒前
14秒前
思源应助007采纳,获得10
15秒前
lalala发布了新的文献求助10
15秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970632
求助须知:如何正确求助?哪些是违规求助? 3515261
关于积分的说明 11177794
捐赠科研通 3250448
什么是DOI,文献DOI怎么找? 1795314
邀请新用户注册赠送积分活动 875781
科研通“疑难数据库(出版商)”最低求助积分说明 805073